surpass cvot tirzepatide results In patients with type 2 diabetes and atherosclerotic cardiovascular disease, was noninferior to dulaglutide with respect to major cardiovascular events. Full SURPASS-CVOT trial results: https://nej.md/4qd5rLx SURPASS-CVOT trial: Tirzepatide was non-inferior

NO PROBLEM

Second Natures peer-reviewed study published in JMIR Formative Research (2025) compared both medications within our programme: 3 Tirzepatide (Mounjaro) cohort (209 people): 22.1% average weight loss at 12 months 95.2% achieved at least 10% weight loss 83.7% achieved at least 15% weight loss Semaglutide (Wegovy) cohort (130 people): 17.1% average weight loss at 12 months 83.1% achieved at least 10% weight loss 56.2% achieved at least 15% weight loss Both cohorts exceeded clinical trial results, suggesting that comprehensive behavioural support enhances outcomes regardless of which medication you use

Trinidad and his medical assistants and other employees

Dual agonism may provide greater consistency of response across diverse patient populations by targeting multiple mechanisms simultaneously

This is not trivial

If you are very lean, some providers recommend pinching the skin and injecting at a 45-degree angle with a slightly longer needle